糖尿病肾病患者肠道菌群及炎症因子变化的临床意义

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (582 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical significance of intestinal flora and inflammatory factors in patients with diabetic nephropathy. Methods A total of 101 patients with type 2 diabetes mellius (T2DM) who were hospitalized in the Sixth Affiliated Hospital of South China University of Technology from January to December 2019 were selected as the study subjects. According to the 24 h urinary albumin excretion rate (UAER), they were divided into group A (UAER≤30 mg/24 h, diabetic normal proteinuria, n=49), group B (30 mg/24 h<UAER≤300 mg/24 h, diabetic microproteinuria, n=30) and group C (UAER>300 mg/24 h, diabetic nephropathy, n=22), and 25 healthy subjects were selected as group D at the same time. The difference of intestinal flora was analyzed by traditional bacterial culture method, and the levels of inflammatory factor interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were detected, and the correlation was analyzed. Results The Bifidobacterium and Clostridium in group C were lower than those in group A, group B and group D, and the differences were statistically significant (P<0.05). Lactobacillus in group C was lower than that in group D, and the difference was statistically significant (P<0.05). The levels of IL-6 and TNF-α in group C were higher than those in group A, group B and group D, and the differences were statistically significant (P<0.05). The levels of IL-6 and TNF-α were negatively correlated with Bifidobacterium and Clostridium (P<0.05). Conclusion There are significant differences in intestinal flora in patients with diabetic nephropathy. With the increased expression of inflammatory factors, intestinal flora may mediate the occurrence of inflammation and participate in the occurrence and development of diabetic nephropathy.

Key words： Diabetic nephropathy Clinical stages Intestinal flora Probiotics Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Shiqiang
	LIU Chunlin
	WU Qingnian

Cite this article:

GUO Shiqiang,LIU Chunlin,WU Qingnian. Clinical significance of intestinal flora and inflammatory factors in patients with diabetic nephropathy[J]. 中国当代医药, 2022, 29(21): 23-26.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I21/23

[1]	Wang L，Gao P，Zhang M，et al.Prevalence and ethnic pattern of diabetes and Prediabetes in China in 2013[J].JAMA，2017，317（24）：2515-2523.
[2]	张娟，焦雅丽，王振国，等.肠道菌群失调与慢性肾脏病相互作用的研究进展[J].实用临床医药杂志，2021，25（14）：98-102.
[3]	Sato J，Kanazawa A，Ikeda F，et al.Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes[J].Diabetes Care，2014，37（8）：2343-2350.
[4]	Vrieze A，Nood EV，Holleman F，et al.Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome[J].Gastroenterology，2012，143（4）：913-916.
[5]	American Diabetes Association.Professional Practice Committee for the Standards of Medical Care in Diabetes-2016[J].Diabetes Care，2016，39（Suppl 1）：S107-S108.
[6]	Inker LA，Schmid CH，Tighiouart H，et al.CKD-EPI Investigators.Estimating glomerular filtration rate from serum creatinine and cystatin C[J].N Engl J Med，2012，367（1）：20-29.
[7]	Ohkusa T，Ozaki Y，Satoc，et al.Long-term ingestion of lactosucrose increases Bifidobacterium sp.in human fecal flora[J].Digestion，1995，56（5）：415-420.
[8]	孙雅娴.早期肾功改变的2型糖尿病患者肠道菌群分析[D].大连：大连医科大学，2016.
[9]	暴旭广，王忠伟，何彦，等.2型糖尿病和糖尿病肾病状态下肠道菌群失衡模式研究[J].中华检验医学杂志，2019， 42（6）：469-478.
[10]	李雷，张帆，方飞，等.糖尿病肾病患者肠道菌群分布变化与炎症指标相关性分析[J].中华内分泌外科杂志，2020， 14（6）：507-510.
[11]	Morrison DJ，Preston T.Formation of short chain fatty acids by the gut microbiota and their impact on human metabo-lism[J].Gut Microbes，2016，7（3）：189-200.
[12]	Marzocco S，Fazeli G，Micco LD，et al.Supplementation of Short-Chain Fatty Acid，Sodium Propionate，in Patients on Maintenance Hemodialysis：Beneficial Effects on Inflammatory Parameters and Gut-Derived Uremic Toxins，A Pilot Study （PLAN Study）[J].J Clin Med，2018，7（10）：315.
[13]	Khan S，Imran A，Malik A，et al.Bacterial imbalance and gut pathologies：Association and contribution of E.coli in inflammatory bowel disease[J].Crit Rev Clin Lab Sci，2019， 56（1）：1-17.
[14]	Wong J，Piceno YM，DeSantis TZ，et al.Expansion of urease-and uricase-containing，indole-and p-cresol-forming and contraction of short-chain fatty acid-producing intestinal microbiota in ESRD[J].Am J Nephrol，2014，39（3）：230-237.
[15]	谢小慧，代思源，戴艳玲，等.基于肠-肾轴理论浅析膳食纤维对慢性肾病的影响[J].中南大学学报（医学版），2020，45（2）：193-197.
[16]	Winther SA，Henriksen P，Vogt JK，et al.Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria[J].Diabetologia，2020，63（12）：2713-2724.
[17]	Yang T，Richards EM，Pepine CJ，et al.The gut microbiota and the brain-gut-kidney axis in hypertension and chronic kidney disease[J].Nat Rev Nephrol，2018，14（7）：442-456.
[18]	赵悦，王俭勤.炎症在糖尿病肾病中的研究进展[J].新医学，2021，52（7）：477-481.
[19]	Perraudeau F，McMurdie P， Bullard J，et al.Improvements to postprandial glucose control in subjects with type 2 diabetes：a multicenter，double blind，randomized placebo-controlled trial of a novel probiotic formulation[J].BMJ Open Diabetes Res Care，2020，8（1）：e001319.
[20]	Conteh AR，Huang R.Targeting the gut microbiota by Asian and Western dietary constituents：a new avenue for diabetes[J].Toxicol Res （Camb），2020，9（4）：569-577.